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Background: The aim of this study was to investigate the ability of a glucosamine-containing 
supplement to improve locomotor functions in subjects with knee pain.
Methods: A randomized, double-blind, placebo-controlled, parallel-group comparative study was 
conducted for 16 weeks in 100 Japanese subjects (age, 51.8±0.8 years) with knee pain. Subjects 
were randomly assigned to one of the two supplements containing 1) 1,200 mg of glucosamine 
hydrochloride, 60 mg of chondroitin sulfate, 45 mg of type II collagen peptides, 90 mg of quercetin 
glycosides, 10 mg of imidazole peptides, and 5 μg of vitamin D per day (GCQID group, n=50) or 
2) a placebo (placebo group, n=50). Japanese Knee Osteoarthritis Measure, visual analog scale 
score, normal walking speed, and knee-extensor strength were measured to evaluate the effects 
of the supplement on knee-joint functions and locomotor functions.
Results: In subjects eligible for efficacy assessment, there was no significant group × time 
interaction, and there were improvements in knee-joint functions and locomotor functions in 
both groups, but there was no significant difference between the groups. In subjects with mild-
to-severe knee pain at baseline, knee-extensor strength at week 8 (104.6±5.0% body weight 
vs 92.3±5.5% body weight, P=0.030) and the change in normal walking speed at week 16 
(0.11±0.03 m/s vs 0.05±0.02 m/s, P=0.038) were significantly greater in the GCQID group 
than in the placebo group. Further subgroup analysis based on Kellgren–Lawrence (K–L) grade 
showed that normal walking speed at week 16 (1.36±0.05 m/s vs 1.21±0.02 m/s, P,0.05) was 
significantly greater in the GCQID group than in the placebo group in subjects with K–L grade I. 
No adverse effect of treatment was identified in the safety assessment.
Conclusion: In subjects with knee pain, GCQID supplementation was effective for relieving 
knee pain and improving locomotor functions.
Keywords: normal walking speed, knee-extensor strength, quercetin glycosides, imidazole 
peptides, vitamin D
Introduction
In Japan, people aged 65 years and older comprise .21% of the population, and the 
nation is becoming a super-aged society more rapidly than any other country. In 2007, 
the Japanese Orthopaedic Association (JOA) proposed the concept of “locomotive 
syndrome”, which refers to those elderly individuals who require nursing-care services 
because of problems with the locomotor organs or because they are at risk for conditions 
for which they may need such services in the future.1 Locomotive syndrome is caused 
mainly by age-related locomotor organ diseases such as osteoporosis and osteoarthritis 
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(OA) or age-related locomotor dysfunctions such as decline 
in walking speed and loss of muscle strength.2,3
OA is the most common joint disease, which causes pain 
in elderly patients. The knee is most frequently affected by 
OA because it is a weight-bearing joint, and knee OA impairs 
locomotor functions such as walking speed.4 According to 
the Research on Osteoarthritis Against Disability (ROAD) 
study, .25 million Japanese people aged 40 years and older 
have been estimated to have radiographically determined 
Kellgren–Lawrence (K–L) grade II or higher joint-space 
narrowing.5,6 Previous studies reported that walking speed 
was associated with survival in older adults and that muscle 
weakness is the highest risk factor for falling, which can 
result in being bedridden.7,8 Therefore, preventing these 
locomotor dysfunctions is considered essential to maintain 
quality of life.
We previously demonstrated that an orally adminis-
tered supplement containing glucosamine hydrochloride, 
chondroitin sulfate, and quercetin glycosides (GCQ) was 
effective for relieving knee pain.9,10 Supplements containing 
glucosamine and chondroitin sulfate have been widely used 
for the management of knee pain in OA.11–13 Nonsteroidal 
anti-inflammatory drugs (NSAIDs) relieve knee pain 
associated with OA and improve locomotor functions in 
patients with knee OA.14 These facts led us to speculate that 
glucosamine-containing supplements, as well as NSAIDs, 
could contribute to improved locomotor functions such as 
knee-extensor strength and walking speed.
Quercetin, one of the flavonoids, which is widely distrib-
uted in plants and fruits, has been reported to suppress the 
atrophy of skeletal muscle in vivo.15 Imidazole peptides are 
distributed mainly in the muscles of animals and have been 
reported to attenuate muscle fatigue in humans.16 Further-
more, vitamin D is a nutrient that supports bone metabolism, 
and several studies have demonstrated its benefit in maintain-
ing musculoskeletal functions and reducing the risk of falls 
in the elderly.17,18
In the present study, we investigated the effects of 
16 weeks of treatment with a supplement containing glu-
cosamine hydrochloride, chondroitin sulfate, type II collagen 
peptides, quercetin glycosides, imidazole peptides, and 
vitamin D (GCQID) on locomotor functions in subjects 
with knee pain.
Methods
study design and participants
A randomized, double-blind, placebo-controlled, parallel-
group comparative study was designed to assess the efficacy 
and safety of GCQID supplementation in Japanese women 
and men aged 40–74 years. Inclusion criteria were the pres-
ence of knee pain, confirmed using the walking subscale 
of the JOA criteria (#25 points for either the left or right 
knee joint);19 visual analog scale (VAS) score for knee 
pain ($20 mm using the first (I) item of the Japanese Knee 
Osteoarthritis Measure [JKOM]);20 and K–L grades 0–II.5 
All participants received an explanation about the study from 
the medical investigators, and written informed consent was 
obtained prior to enrollment in the study. Exclusion criteria 
were the following: faster walking speed ($1.6 m/s); pres-
ence of hyperuricemia, diabetes, cardiovascular disease, 
hepatic disease, renal disease, or heart disease; treatment 
with exercise, diet, or medicine that may have an effect on 
the weight; presence of rheumatic arthritis that may cause 
joint pain; surgical treatment of knee joint(s) undergone or 
its necessity; needs to undergo pharmacological articular 
treatments during the study period; intra-articular hyaluronic 
acid within 2 weeks or corticosteroids within 3 months before 
inclusion; a history of osseous or articular diseases other than 
OA within the past 3 months; routine use of health food or 
medicine that may have an effect on the evaluation of the 
study; daily use of a cane; performing daily or occasional 
vigorous exercise; treatment with warfarin; bronchial asthma, 
respiratory disease, or potential for developing allergy to the 
test supplement; pregnant women; nursing mothers or women 
of child-bearing potential; and presence of any medical con-
dition judged by the medical investigator.
One hundred participants were enrolled in the study, 
which was performed from February 2012 to September 2012 
at a clinical services center in Japan. All subjects, who had 
never taken the same or similar type of supplement before, 
were recruited in and around Osaka, Kyoto, Japan, through 
a volunteer bank managed by HUMA R&D Co, Inc. (Tokyo, 
Japan). Once radiographs were obtained, each subject’s K–L 
grade was determined by an orthopedic surgeon. The study 
protocol was approved by the institutional ethics commit-
tee of East One Medical Clinic (Tokyo, Japan) and was 
conducted in accordance with the principles of the amended 
Declaration of Helsinki and Ethical Guidelines for Epide-
miological Research (issued by the Japanese government 
in 2008).
Treatment and group assignment
The GCQID contained 1,200 mg of glucosamine hydrochlo-
ride, 300 mg of shark cartilage extract (60 mg as chondroitin 
sulfate, 45 mg as type II collagen peptides), 90 mg of 
quercetin glycosides, 100 mg of fish meat extract (10 mg 
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as imidazole peptides [anserine and carnosine]), and 5 μg 
(200 IU) of vitamin D in eight tablets. Placebo just con-
tained base material such as dextrin, and it did not contain 
components such as glucosamine hydrochloride, chondroitin 
sulfate, type II collagen peptides, quercetin glycosides, imi-
dazole peptides, and vitamin D in eight tablets. Subjects were 
randomly distributed to the two treatment groups in terms of 
normal walking speed, age, sex, average steps walked in a 
week, body mass index, and the aggregate scores for the JOA 
criteria and sequentially assigned to receive either GCQID 
(GCQID group) or placebo (placebo group). The randomiza-
tion codes for enrolled subjects were held by an appointed 
person who was not involved in the study. The GCQID and 
placebo tablets were manufactured by Suntory Wellness Ltd 
specifically for the purpose of the present study to ensure that 
the placebo tablet was indistinguishable from the GCQID 
tablet in appearance, taste, and packaging. Allocation was 
preassigned on the basis of randomization numbers and 
was concealed from the subjects, the investigators, and the 
researchers who recruited and assessed participating sub-
jects. All subjects were instructed to take eight tablets once 
a day and to record in their study diary whether they took 
the tablets or not.
Efficacy assessment
The efficacy of GCQID supplementation was assessed on the 
basis of measures of knee-joint functions and locomotor func-
tions. Data on knee-joint functions were collected at baseline 
and at weeks 4, 8, 12, and 16. Data on locomotor functions 
were collected at baseline and at weeks 8 and 16. Serum 
25-hydroxy vitamin D (25-OHD) levels were measured at 
baseline and week 16 as an assessment of efficacy. Exclu-
sion criteria based on efficacy assessment were as follows: 
taking ,80% of the test supplement, performing actions that 
affected the reliability of the efficacy assessment (subjects 
who had too great a difference [$±0.25 m/s] in measured 
walking speed between the screening period and baseline), 
and noncompliance with the clinical protocol.
Knee-joint functions were measured as score for JKOM 
item I (VAS score for JKOM knee pain), total score for 
JKOM items II–V (JKOM total score),20 and VAS score for 
pain on walking. VAS score was measured on a scale from 
0 to 100, where 0 indicated no pain and 100 indicated the 
worst pain ever experienced. Subjects self-reported these 
measures on a website available only to the study participants. 
JKOM total score is a self-administered, disease-specific 
measure, consisting of 25 items that cover four different 
categories: “II: pain and stiffness in knees”, “III: conditions 
in daily life”, “IV: general activities”, and “V: health condi-
tions”. An overall result was assessed by summing the scores 
from the 25 items, with results ranging from 0 (no complaint) 
to 100 (most severe condition possible).
Locomotor functions were measured as walking speed 
and knee-extensor strength. For the measurement of walking 
speed, subjects were instructed to walk 10 m two times at 
their usual speed. The time it took to walk the intermedi-
ate 6 m was measured, and the average of two times was 
calculated as a subject’s walking speed. We measured the 
knee-extensor strength (torque) using a procedure previously 
described.21 For the measurement of knee-extensor strength, 
subjects performed isometric knee extensions on a custom 
dynamometer mounted force transducer (LU-100KSE; 
Kyowa Electronic Instruments, Tokyo, Japan). During the 
contraction of muscle, both knee joint and hip angles were 
flexed at 90° (180° was fully extended). For the maximal 
voluntary contractions of subjects, knee extension force 
exerted by knee extensor muscles was gradually increased 
from baseline to maximum in 2–3 seconds and then sustained 
at maximum for 2 seconds. Subjects carried out three trials 
with each leg, and the highest of the three was used. The sum 
of the values for both legs per unit body weight represented 
knee-extensor strength. The number of steps walked weekly, 
performed in leisurely fashion, and associated with activities 
of daily living was monitored using a pedometer.
A stratified analysis of subjects with mild-to-severe knee 
pain (VAS score for JKOM knee pain $20 at baseline) was 
also performed. Using the OA criteria from the ROAD study,6 
subgroups with or without radiographic OA (K–L grade $II 
or #I, respectively) were then analyzed further.
safety assessment
The safety of GCQID supplementation was assessed on 
the basis of the incidence and severity of treatment-related 
adverse events reported throughout the 16-week intervention 
period. Furthermore, enrolled subjects were requested to 
visit a clinic to undergo laboratory tests (hematology, blood 
biochemistry, and urinalysis) and physical examinations 
at baseline and week 16 as part of the safety assessment. 
Blood samples were obtained with the subjects in a fasting 
state, and urine samples from the morning’s second void 
were collected.
statistical analysis
All data are expressed as mean ± standard error unless 
otherwise specified. Baseline data were compared between the 
groups using the unpaired t-test for quantitative variables and 





χ2-test for qualitative variables. Two-way repeated-measures 
analysis of variance was used for analyzing the differences 
in the effect of intervention, and post hoc analysis was con-
ducted. In case of no significant group × time interaction, com-
parisons between groups at each time point were performed 
using the Mann–Whitney U-test for JKOM total score and 
the unpaired t-test for physical and laboratory test variables, 
VAS score for JKOM knee pain, VAS score for pain on walk-
ing, normal walking speed, and knee-extensor strength. For 
reference, changes in measurements during the intervention 
were compared with baseline using a paired t-test for physical 
and laboratory test variables; the Steel test for JKOM total 
score; and Dunnett’s test for VAS score for JKOM knee pain, 
VAS score for pain on walking, normal walking speed, and 
knee-extensor strength. P-values ,0.05 were considered 
significant. Effect sizes (d values for parametric variables 
and r values for nonparametric variables) were calculated 
in the measures in which there were significant differences 
between the groups. All statistical analyses were carried out 
using IBM SPSS Statistics for Windows, Version 21.0 (IBM 
Corporation, Armonk, NY, USA) and Ekuseru-Toukei 2010 
for Windows (Social Survey Research Information Co, Ltd, 
Tokyo, Japan).
Results
Table 1 presents the baseline characteristics for all enrolled 
subjects. No significant difference was observed between 
the groups for any characteristic. The 100 subjects who 
took the test supplement were eligible for safety assessment. 
Three subjects dropped out of the study because of 
adverse events (GCQID: 1, placebo: 1) or personal reasons 
(GCQID: 1), and 15 subjects were excluded from efficacy 
assessment because of efficacy-assessment exclusion criteria: 
taking ,80% of the test supplement (GCQID: 1); performing 
actions that affected the reliability of the efficacy assessment 
(too great a difference [$±0.25 m/s] in measured walking 
speed between the screening period and baseline) (GCQID: 1, 
placebo: 2); and noncompliance with the clinical protocol 
(GCQID: 5, placebo: 6). Thus, 41 subjects in the GCQID 
group and 41 in the placebo group were deemed eligible for 
efficacy assessment.
Table 2 shows the changes in knee-joint functions and 
locomotor functions during the 16-week intervention period. 
There was no significant group × time interaction in all 
measures for efficacy assessment. There was no significant 
difference between the groups in all measures for efficacy 
assessment except for serum 25-OHD levels. Serum 25-OHD 
levels were significantly greater in the GCQID group 
than in the placebo group at week 16 (31.9±0.8 ng/mL vs 
28.5±1.1 ng/mL, P,0.05, d=0.49).
A stratified analysis of subjects with mild-to-severe knee 
pain (VAS score for JKOM knee pain $20 at baseline) was 
performed. No significant difference was observed between 
the groups for any characteristic (Table 3). There was no sig-
nificant group × time interaction in all measures for efficacy 
assessment except for serum 25-OHD levels, and knee-extensor 
strength was significantly greater in the GCQID group than 
in the placebo group at week 8 (P,0.05, d=0.65; Table 4). 
Table 1 The baseline characteristics of the study population
Variables GCQID groupa  
(n=50)
Placebo groupa  
(n=50)
P-value
Age (years) 51.9±1.2 51.6±1.1 0.852
sex (male/female) 22/28 22/28 1.000
height (cm) 162.0±1.0 163.0±1.2 0.507
Body weight (kg) 60.3±1.3 62.3±1.3 0.397
Body mass index (kg/m2) 22.9±0.5 23.3±0.5 0.500
systolic blood pressure (mmhg) 129.7±2.1 125.7±2.2 0.198
Diastolic blood pressure (mmhg) 81.1±1.5 80.2±1.5 0.704
heart rate (beats/min) 71.8±1.6 75.4±1.7 0.131
normal walking speed (m/s) 1.28±0.02 1.29±0.02 0.912
Knee-extensor strength (% body weight)b 100.0±5.2 93.1±5.3 0.360
JOA criteria aggregate scores (points) 180.4±1.3 177.9±2.0 0.919
VAs score for pain on walking (mm) 25.5±3.0 21.3±2.7 0.297
Average daily steps walked in a week (steps) 6,511±465 6,192±446 0.622
K–l grades (0, I, II) 14, 25, 11 16, 23, 11 0.897
Notes: aAll values except sex and K–l grade are expressed as mean ± standard error. bKnee-extensor strength was measured in both knees and expressed as total strength 
of both knees.
Abbreviations: gCQID, glucosamine hydrochloride, chondroitin sulfate, type II collagen peptides, quercetin glycosides, imidazole peptides, and vitamin D; JOA, Japanese 
Orthopaedic Association; K–l, Kellgren–lawrence; VAs, visual analog scale.
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Table 2 Changes in knee-joint functions and locomotor functions in subjects eligible for efficacy assessmenta
Variables Values at each time pointb Two-way ANOVA 
(group × time)
P-value
Baseline Week 4 Week 8 Week 12 Week 16
JKOM
(I) VAs score for knee pain (mm)
gCQID 27.0±3.4 24.2±3.1 17.1±2.5* 14.0±3.0** 9.8±2.3** 0.939
Placebo 28.5±3.0 24.2±3.3 18.7±3.2* 13.0±2.5** 11.4±2.1**
(II–V) Total score (points)
gCQID 14.0±1.6 11.8±1.5 9.2±1.0* 9.1±1.2** 8.5±1.1** 0.362
Placebo 13.0±1.0 12.6±1.1 11.0±1.1 10.5±1.2 9.3±0.9*
VAs score for pain on walking (mm)
gCQID 23.7±3.3 16.2±2.8 12.5±2.5** 9.6±2.3** 7.1±2.2** 0.216
Placebo 18.6±2.2 16.1±2.9 15.0±3.1 11.6±2.3* 7.3±1.6**
normal walking speed (m/s)
gCQID 1.28±0.03 1.32±0.03* 1.35±0.02** 0.524
Placebo 1.28±0.02 1.32±0.02* 1.33±0.02**
Knee-extensor strength (% body weight)c
gCQID 95.9±5.0 104.6±5.0* 104.5±4.9* 0.546
Placebo 88.1±5.8 92.3±5.5 92.6±5.6
Notes: agCQID group (n=41) and placebo group (n=41). bValues expressed as mean ± standard error. cKnee-extensor strength was measured in both knees and expressed 
as the total strength of both knees. *P,0.05 and **P,0.01 compared with baseline value.
Abbreviations: AnOVA, analysis of variance; gCQID, glucosamine hydrochloride, chondroitin sulfate, type II collagen peptides, quercetin glycosides, imidazole peptides, 
and vitamin D; JKOM, Japanese Knee Osteoarthritis Measure; VAs, visual analog scale.
Table 3 Baseline characteristics of subjects selected for stratified analyses
Variables GCQID groupa  
(n=23)
Placebo groupa  
(n=25)
P-value
Age (years) 51.5±1.7 50.6±1.4 0.702
sex (male/female) 9/14 12/13 0.536
height (cm) 162.3±1.7 163.8±1.7 0.527
Body weight (kg) 63.1±2.8 62.9±2.3 0.956
Body mass index (kg/m2) 23.8±0.7 23.4±0.7 0.696
systolic blood pressure (mmhg) 131.1±3.6 126.6±3.2 0.352
Diastolic blood pressure (mmhg) 82.7±2.5 82.4±2.5 0.924
heart rate (beats/min) 72.0±2.3 76.7±2.3 0.153
normal walking speed (m/s) 1.26±0.04 1.25±0.03 0.957
Knee-extensor strength (% body weight)b 93.4±6.7 81.5±7.6 0.248
JOA criteria aggregate scores (points) 178.9±2.0 175.4±2.9 0.522
VAs score for pain on walking (mm) 33.3±4.3 24.5±3.0 0.103
Average daily steps walked in a week (steps) 6,221±510 6,386±599 0.837
K–l grades (0, I, II) 6, 14, 3 7, 12, 6 0.563
Notes: aAll values except sex and K–l grade are expressed as mean ± standard error. bKnee-extensor strength was measured in both knees and expressed as total strength 
of both knees.
Abbreviations: gCQID, glucosamine hydrochloride, chondroitin sulfate, type II collagen peptides, quercetin glycosides, imidazole peptides, and vitamin D; JOA, Japanese 
Orthopaedic Association; K–l, Kellgren–lawrence; VAs, visual analog scale.
The change in JKOM total score at week 8 (P,0.05, r=0.37) 
and the change in normal walking speed at week 16 (P,0.05, 
d=0.62) were significantly greater in the GCQID group than in 
the placebo group (Figure 1). There was a significant group × 
time interaction in serum 25-OHD levels, and the change in 
serum 25-OHD levels at week 16 was significantly greater in 
the GCQID group than in the placebo group (11.9±1.8 ng/mL 
vs 6.9±1.3 ng/mL, P,0.05, d=0.80).
Subgroup analysis based on K–L grade in subjects with 
mild-to-severe knee pain at baseline was also performed. 
There was no significant group × time interaction, and there 
was no significant difference between the groups in JKOM 
total score and normal walking speed both in subjects 
with K–L grades $II and in subjects with K–L grade #I 
(Table 5). In subjects with K–L grades $II, the change in 
JKOM total score at week 8 was significantly greater in the 





Table 4 Changes in knee-joint functions and locomotor functions at each time point in subjects with mild-to-severe knee pain at 
baselinea
Variables Values at each time pointb Two-way ANOVA 
(group × time)
P-value
Baseline Week 4 Week 8 Week 12 Week 16
JKOM
(I) VAs score for knee pain (mm)
gCQID 41.5±4.0 31.2±4.3 19.9±2.9** 15.4±4.4** 9.9±3.4** 0.490
Placebo 40.0±3.1 28.6±3.9* 22.4±3.5** 18.5±3.7** 16.4±3.0**
(II–V) Total score (points)
gCQID 17.6±2.5 14.3±2.5 10.3±1.5* 10.7±2.0** 9.2±1.7** 0.169
Placebo 15.2±1.3 13.7±1.6 13.3±1.6 12.2±1.7 10.6±1.2
VAs score for pain on walking (mm)
gCQID 33.3±4.3 22.2±4.3* 14.3±3.4** 12.0±3.9** 8.7±3.8** 0.067
Placebo 24.5±3.0 20.0±3.7 17.9±3.4* 16.6±3.4* 9.6±2.4**
normal walking speed (m/s)
gCQID 1.26±0.04 1.32±0.04* 1.37±0.04** 0.095
Placebo 1.25±0.03 1.28±0.03 1.30±0.03*
Knee extensor strength (% body weight)c
gCQID 93.4±6.7 108.4±5.3**,§ 109.8±5.6** 0.330
Placebo 81.5±7.6 88.0±7.3 92.0±7.8**
Notes: agCQID group (n=23) and placebo group (n=25). bValues are expressed as mean ± standard error. cKnee-extensor strength was measured in both knees and 
expressed as total strength of both knees. *P,0.05 and **P,0.01 compared with values at baseline. §P,0.05 compared with placebo.
Abbreviations: AnOVA, analysis of variance; gCQID, glucosamine hydrochloride, chondroitin sulfate, type II collagen peptides, quercetin glycosides, imidazole peptides, 
and vitamin D; JKOM, Japanese Knee Osteoarthritis Measure; VAs, visual analog scale.
Figure 1 Changes in magnitude of (A) JKOM total score (items II–V) and (B) normal walking speed.
Notes: gCQID group (n=23) and placebo group (n=25). §P,0.05 compared with placebo group. Values are expressed as mean ± standard error.
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GCQID group than in the placebo group (−20.3±12.5 points 
vs 0.5±1.5 points, P,0.05, r=0.74). The change in normal 
walking speed tended to be greater in the GCQID group 
than in the placebo group at week 16, but the difference 
was not significant (P=0.08). Similarly, in subjects with 
K–L grade #I, the change in normal walking speed tended 
to be greater in the GCQID group than in the placebo group 
at week 16 (P=0.08).
Further analysis of subjects with K–L grade I (14 in the 
GCQID group and 12 in the placebo group) showed that there 
was no significant group × time interaction in JKOM total 
score and normal walking speed, and the change in JKOM 
total score was significantly greater in the GCQID group than 
in the placebo group at week 8 (−6.2±1.5 points vs −1.8±0.9 
points, P,0.05, r=0.42). Normal walking speed in the 
GCQID group was significantly greater than in the placebo 
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Table 5 Changes in JKOM total score (items II–V) and normal walking speed at each time point in subjects with mild-to-severe knee 
pain and baseline K–l grade $II or #Ia
Variables K–L grades $II K–L grades #I
JKOM total score  
(points)
Normal walking speed  
(m/s)
JKOM total score  
(points)
Normal walking speed 
(m/s)
Values at each 
time pointb
GCQID Placebo GCQID Placebo GCQID Placebo GCQID Placebo
Baseline 29.7±14.8 13.7±2.6 1.16±0.07 1.28±0.04 15.8±1.8 15.7±1.5 1.27±0.04 1.25±0.04
Week 4 24.3±14.9 12.0±3.4 12.9±2.0 14.3±2.0
Week 8 9.3±2.4 14.2±3.8 1.31±0.13 1.30±0.05 10.5±1.7 13.1±1.8 1.33±0.05 1.28±0.04
Week 12 9.3±1.5 13.0±5.3 10.9±2.3 11.9±1.6
Week 16 8.0±2.6 9.3±2.8 1.35±0.08 1.35±0.06* 9.4±1.9* 11.0±1.4 1.37±0.04** 1.28±0.04
Two-way AnOVA  
(group × time)
P-value
0.082 0.064 0.634 0.193
Notes: agCQID group (n=3), placebo group (n=6) for K–l grade $II. gCQID group (n=20), placebo group (n=19) for K–l grade #I. bValues expressed as mean ± standard 
error. *P,0.05 and **P,0.01 compared with baseline values.
Abbreviations: AnOVA, analysis of variance; gCQID, glucosamine hydrochloride, chondroitin sulfate, type II collagen peptides, quercetin glycosides, imidazole peptides, 
and vitamin D; JKOM, Japanese Knee Osteoarthritis Measure; K–l, Kellgren–lawrence.
group at week 16 (1.36±0.05 m/s vs 1.21±0.02 m/s, P,0.05, 
d=0.68). There was no significant difference between the 
groups in subjects with K–L grade 0 (data not shown).
Significant changes in several blood biochemical and 
hematological variables were observed in both groups dur-
ing the 16-week intervention (Table S1), but the values 
were judged by the investigators to have remained within 
the normal range and to be medically unrelated to the treat-
ment. There were also no abnormal changes in physical 
parameters and urinalysis, including proteinuria, glucosuria, 
and hematuria (data not shown). Some subjects in both groups 
reported experiencing one or more adverse events during 
the intervention. However, there was no between-group 
difference in frequency or pattern of events (Table S2). All 
self-reported adverse events were transient and of mild or 
intermediate intensity. Moreover, no adverse effect of treat-
ment was identified when these results were analyzed on an 
individual-subject basis.
Discussion
The present study was conducted to evaluate effects of a 
glucosamine-containing supplement (GCQID) on locomotor 
functions in subjects with knee pain.
The efficacy assessment revealed that GCQID supplemen-
tation improved JKOM total score, normal walking speed, 
and knee-extensor strength in subjects with mild-to-severe 
knee pain at baseline better than the placebo (Table 4 and 
Figure 1). Using OA criteria used in the ROAD study,6 sub-
group analysis based on K–L grade was performed to investi-
gate the efficacy of GCQID supplementation with or without 
radiographic OA. We found that GCQID supplementation 
only tended to improve normal walking speed more than 
placebo in subjects with K–L grade $II or #I, and it signifi-
cantly improved both JKOM total score and normal walking 
speed more than placebo in subjects with K–L grade I. These 
results suggest that GCQID supplementation can be effective 
at improving knee-joint functions and locomotor functions 
in subjects with mild-to-severe knee pain, especially those 
with K–L grade I joint-space narrowing.
The ability of GCQID supplementation to relieve knee 
pain may be explained mainly by the anti-inflammatory and 
chondroprotective activities of glucosamine hydrochloride,22,23 
chondroitin sulfate,24 and quercetin,25,26 as described in 
a previous study on GCQ supplementation.10 Pain sig-
nals suppress muscle performance, and knee OA impairs 
locomotor functions such as walking speed.4 Najm et al14 
showed that NSAIDs improved knee-joint functions and 
locomotor functions at the same time in patients with knee 
OA. Similarly, the improvement in knee-joint functions 
observed with GCQID supplementation in the present study 
may partially contribute to improved locomotor functions in 
subjects with knee pain. Mukai et al15 confirmed that quercetin 
can prevent atrophy caused by muscle disuse by attenuating 
the expression of ubiquitin ligases, and Horii et al27 revealed 
that a type of imidazole peptide increased muscle blood flow 
via changes in muscle sympathetic nerve activity, suggesting 
that quercetin glycosides and imidazole peptides in GCQID 
can directly affect muscle functions. Lower serum 25-OHD 
levels are associated with impaired locomotor functions.28 
The 16-week intervention with GCQID supplementation 
elevated serum 25-OHD levels compared with the placebo 
group in subjects with mild-to-severe knee pain, suggesting 





that the elevated serum 25-OHD levels in the GCQID group 
may partially contribute to improved locomotor functions, 
although there was a significant group × time interaction. 
In Japan, serum 25-OHD levels are lowest at the end of 
winter and highest at the end of summer,29 and the present 
study was conducted from winter to summer. Therefore, the 
time effect in elevated serum 25-OHD levels can be partly 
explained by seasonal changes, which may also partially 
contribute to improved locomotor functions.
In the present study, GCQID supplementation improved 
locomotor functions. An increase in muscle strength with 
GCQID supplementation might be expected to lower the risk 
of falling because muscle weakness is the highest risk factor 
for falling.6 It has been reported that walking speed is associ-
ated with survival in older adults5 and that the ingestion of 
glucosamine or chondroitin is associated with decreased total 
mortality.30 Therefore, GCQID supplementation may have a 
beneficial effect on survival rate. Further research is needed 
to elucidate the effect of supplements such as GCQID, which 
improve locomotor functions, on survival rate.
In the safety assessment, no abnormalities in any labora-
tory tests were observed and no treatment-related adverse 
events were experienced during the intervention period, 
which suggests that GCQID is a safe supplement.
There are some limitations to the present study. First, 
the study was conducted over a relatively short period and 
the sample size was relatively small. Therefore, a long-term 
study with a large sample size may be needed to clarify the 
effect of GCQID supplementation on locomotor functions. 
Second, because subjects’ daily dietary intake, which might 
have affected knee-joint functions or locomotor functions, 
was not monitored, it must be acknowledged that daily 
diet might have partially affected the efficacy observed in 
the present study. Third, because the GCQID had several 
components, further studies should be conducted to clarify 
the role of each component of the GCQID on locomotor 
functions.
Conclusion
In conclusion, our findings suggest that GCQID supplementa-
tion was safe and effective in improving knee-joint functions 
and locomotor functions in subjects with knee pain.
Acknowledgments
We thank all participants and the professional staff at the 
Graduate School of Human and Environmental Studies at 
Kyoto University for their support of the study and Dr Izumo 
at Suntory Wellness Ltd for his support in the preparation 
of the manuscript. This research was supported by Suntory 
Wellness Ltd.
Disclosure
NK, YO, and HS are employed by Suntory Wellness Ltd, 
which is the sponsor of this study and markets health food 
products, such as the GCQID used in this study. Research 
funding, including travel fees, were provided to TM by 
Suntory Wellness Ltd. The authors report no other conflicts 
of interest in this work.
References
 1. Nakamura K. A “super-aged” society and the “locomotive syndrome”. 
J Orthop Sci. 2008;13(1):1–2.
 2. Schimpl M, Moore C, Lederer C, et al. Association between walking speed 
and age in healthy, free-living individuals using mobile accelerometry – 
a cross-sectional study. PLoS One. 2011;6(8):e23299.
 3. Lindle RS, Metter EJ, Lynch NA, et al. Age and gender comparisons of 
muscle strength in 654 women and men aged 20–93 yr. J Appl Physiol. 
1997;83(5):1581–1587.
 4. Kiss RM. Effect of severity of knee osteoarthritis on the variability of 
gait parameters. J Electromyogr Kinesiol. 2011;21(5):695–703.
 5. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthritis. 
Ann Rheum Dis. 1957;16(4):494–502.
 6. Yoshimura N, Muraki S, Oka H, et al. Prevalence of knee osteoarthritis, 
lumbar spondylosis, and osteoporosis in Japanese men and women: the 
research on osteoarthritis/osteoporosis against disability study. J Bone 
Miner Metab. 2009;27(5):620–628.
 7. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older 
adults. JAMA. 2011;305(1):50–58.
 8. American Geriatrics Society, British Geriatrics Society, American Acad-
emy of Orthopaedic Surgeons Panel on Falls Prevention. Guideline for 
the prevention of falls in older persons. J Am Geriatr Soc. 2001;49(5): 
664–672.
 9. Matsuno H, Nakamura H, Katayama K, et al. Effects of an oral adminis-
tration of glucosamine-chondroitin-quercetin glucoside on the synovial 
fluid properties in patients with osteoarthritis and rheumatoid arthritis. 
Biosci Biotechnol Biochem. 2009;73(2):288–292.
 10. Kanzaki N, Saito K, Maeda A, et al. Effect of a dietary supplement con-
taining glucosamine hydrochloride, chondroitin sulfate and quercetin gly-
cosides on symptomatic knee osteoarthritis: a randomized, double-blind, 
placebo-controlled study. J Sci Food Agric. 2012;92(4):862–869.
 11. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and 
chondroitin for treatment of osteoarthritis: a systematic quality assess-
ment and meta-analysis. JAMA. 2000;283(11):1469–1475.
 12. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of 
glucosamine sulphate on osteoarthritis progression: a randomized, 
placebo-controlled clinical trial. Lancet. 2001;357(9252):251–256.
 13. Kahan A, Uebelhart D, De Vathaire F, Delmas PD, Reginster JY. 
Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis 
progression prevention: a two-year, randomized, double-blind, placebo-
controlled trial. Arthritis Rheum. 2009;60(2):524–533.
 14. Najm WI, Reinsch S, Hoehler F, Tobis JS, Harvey PW. S-adenosyl 
methionine (SAMe) versus celecoxib for the treatment of osteoarthritis 
symptoms: a double-blind cross-over trial. BMC Musculoskelet Disord. 
2004;5:6.
 15. Mukai R, Nakao R, Yamamoto H, Nikawa T, Takeda E, Terao J. 
Quercetin prevents unloading-derived disused muscle atrophy by 
attenuating the induction of ubiquitin ligases in tail-suspension mice. 
J Nat Prod. 2010;73(10):1708–1710.
 16. Maemura H, Goto K, Yoshioka T, Sato M, Takahata Y, Morimatsu F. 
Effects of carnosine and anserine supplementation on relatively high inten-
sity endurance performance. Int J Sport Health Sci. 2006;4:86–94.




glucosamine-containing supplement improves locomotor functions
 17. Bischoff HA, Stähelin HB, Dick W, et al. Effects of vitamin D and 
calcium supplementation on falls: a randomized controlled trial. J Bone 
Miner Res. 2003;18(2):343–351.
 18. Sato Y, Iwamoto J, Kanoko T, Satoh K. Low-dose vitamin D prevents 
muscular atrophy and reduces falls and hip fractures in women after stroke: 
a randomized controlled trial. Cerebrovasc Dis. 2005;20(3):187–192.
 19. The Japanese Orthopaedic Association Japanese Knee Society. Assessment 
Criteria for Knee Diseases and Treatments. Tokyo: Kanehara; 1994.
 20. Akai M, Doi T, Fujino K, Iwaya T, Kurosawa H, Nasu T. An outcome 
measure for Japanese people with knee osteoarthritis. J Rheumatol. 
2005;32(8):1524–1532.
 21. Watanabe K, Kouzaki M, Merletti R, Fujibayashi M, Moritani T. Spatial 
EMG potential distribution pattern of vastus lateralis muscle during 
isometric knee extension in young and elderly men. J Electromyogr 
Kinesiol. 2012;22(1):74–79.
 22. Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW. Glu-
cosamine HCl reduces equine articular cartilage degradation in explant 
culture. Osteoarthritis Cartilage. 2000;8(4):258–265.
 23. Gouze JN, Bordji K, Gulberti S, et al. Interleukin-1beta down-regulates the 
expression of glucuronosyltransferase I, a key enzyme priming glycosamin-
oglycan biosynthesis: influence of glucosamine on interleukin-1beta-me-
diated effects in rat chondrocytes. Arthritis Rheum. 2001;44(2):351–360.
 24. Iovu M, Dumais G, du Souich P. Anti-inflammatory activity of chondroitin 
sulfate. Osteoarthritis Cartilage. 2008;16(suppl 3):S14–S18.
 25. Jackson JK, Higo T, Hunter WL, Burt HM. The antioxidants curcumin 
and quercetin inhibit inflammatory processes associated with arthritis. 
Inflamm Res. 2006;55(4):168–175.
 26. Mamani-Matsuda M, Kauss T, Al-Kharrat A, et al. Therapeutic and 
preventive properties of quercetin in experimental arthritis correlate with 
decreased macrophage inflammatory mediators. Biochem Pharmacol. 
2006;72(10):1304–1310.
 27. Horii Y, Fujisaki Y, Fuyuki R, Nagai K. L-carnosine’s dose-dependent 
effects on muscle sympathetic nerves and blood flow. Neurosci Lett. 2015; 
591:144–148.
 28. Suzuki T, Kwon J, Kim H, et al. Low serum 25-hydroxyvitamin D levels 
associated with falls among Japanese community-dwelling elderly. 
J Bone Miner Res. 2008;23(8):1309–1317.
 29. Ono Y, Suzuki A, Kotake M, et al. Seasonal changes of serum 
25-hydroxyvitamin D and intact parathyroid hormone levels in 
a normal Japanese population. J Bone Miner Metab. 2005;23(2): 
147–151.
 30. Pocobelli G, Kristal AR, Patterson RE, et al. Total mortality risk in rela-
tion to use of less-common dietary supplements. Am J Clin Nutr. 2010; 
91(6):1791–1800.






Table S1 Changes in laboratory values between baseline and week 16
Variablesa Group Values at time point
Baseline Week 16
AsT (IU/l) gCQID 21.3±0.8 20.6±0.9
Placebo 22.1±1.1 19.5±0.8*
AlT (IU/l) gCQID 20.7±1.5 19.7±2.0
Placebo 22.0±1.8 20.2±1.7
AlP (IU/l) gCQID 204.9±8.5 201.3±8.4
Placebo 204.8±8.2 208.8±7.6
lDh (IU/l) gCQID 185.3±3.9 190.9±3.8*
Placebo 184.6±5.4 187.1±3.8
γ-gTP (IU/l) gCQID 30.8±4.3 29.1±4.0
Placebo 30.1±3.4 28.1±3.4
T-Bil (mg/dl) gCQID 0.75±0.05 0.82±0.05*
Placebo 0.72±0.05 0.74±0.06
TP (g/dl) gCQID 7.33±0.05 7.19±0.05*
Placebo 7.26±0.06 7.15±0.05*
Alb (g/dl) gCQID 4.29±0.03 4.31±0.03
Placebo 4.27±0.04 4.29±0.03
CPK (IU/l) gCQID 124.5±12.6 121.3±9.9
Placebo 103.0±6.3 112.7±7.3
Triglyceride (mg/dl) gCQID 105.2±8.0 97.5±8.4
Placebo 109.2±9.0 120.0±11.9
TC (mg/dl) gCQID 220.7±4.7 214.3±4.4
Placebo 223.3±5.0 213.4±5.2**
hDl-C (mg/dl) gCQID 68.7±2.9 65.0±2.7**
Placebo 68.2±2.7 62.5±2.3**
lDl-C (mg/dl) gCQID 128.3±3.5 126.0±3.7
Placebo 130.5±4.5 125.1±4.6*
BUn (mg/dl) gCQID 14.0±0.5 13.3±0.6*
Placebo 13.4±0.4 13.1±0.4
UA (mg/dl) gCQID 4.53±0.18 4.95±0.19**
Placebo 4.82±0.16 5.13±0.17**
Cr (mg/dl) gCQID 0.69±0.02 0.70±0.02
Placebo 0.66±0.02 0.68±0.02*
na (meq/l) gCQID 140.1±0.2 139.9±0.2
Placebo 140.0±0.2 140.5±0.3
K (meq/l) gCQID 4.45±0.05 4.28±0.05**
Placebo 4.48±0.05 4.26±0.05**
Cl (meq/l) gCQID 103.2±0.3 103.9±0.2*
Placebo 103.3±0.3 104.2±0.3**
glucose (mg/dl) gCQID 91.3±1.5 90.5±1.8
Placebo 91.4±1.2 91.3±1.4
hbA1c (%) gCQID 5.00±0.05 4.97±0.05
Placebo 5.07±0.04 5.06±0.04
CrP (mg/dl)b gCQID 0.10±0.02 0.10±0.02
Placebo 0.10±0.02 0.07±0.01
Insulin (μU/ml)b gCQID 5.83±0.58 5.92±0.69
Placebo 5.55±0.65 7.23±0.84
WBC (×103/μl) gCQID 5.74±0.17 5.60±0.16
Placebo 5.94±0.20 5.80±0.19
rBC (×104/μl) gCQID 463.1±4.3 449.0±4.6**
Placebo 466.1±5.4 454.7±5.3**
(Continued)
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Table S1 (Continued)
Variablesa Group Values at time point
Baseline Week 16
hb (g/dl) gCQID 13.9±0.2 13.5±0.2**
Placebo 14.0±0.2 13.7±0.2**
hct (%) gCQID 42.4±0.4 41.1±0.4**
Placebo 42.8±0.5 41.5±0.5**
Plt (×104/μl) gCQID 25.1±0.9 24.2±0.9*
Placebo 25.6±0.9 24.2±0.8**
Notes: All values are expressed as mean ± standard error for gCQID group (n=48) and placebo group (n=49). aOf the 100 subjects eligible for safety assessment, three 
(two in the gCQID group and one in the placebo group) dropped out of the study and did not undergo laboratory examinations at week 16. bValues below the detectable 
limit for CrP and insulin are calculated as 0.05 mg/dl and 2.0 μU/ml, respectively. *P,0.05 and **P,0.01 compared with baseline.
Abbreviations: Alb, albumin; AlP, alkaline phosphatase; AlT, alanine aminotransferase; AsT, aspartate aminotransferase; BUn, blood urea nitrogen; Cl, chloride; 
CPK, creatinine phosphokinase; Cr, creatinine; CrP, C-reactive protein; gCQID, glucosamine hydrochloride, chondroitin sulfate, quercetin glycosides, imidazole peptides, 
and vitamin D; γ-gTP, gamma-glutamyl transpeptidase; hb, hemoglobin; hbA1c, hemoglobin A1c; hct, hematocrit; hDl-C, high-density lipoprotein cholesterol; K, potassium; 
lDh, lactate dehydrogenase; lDl-C, low-density lipoprotein cholesterol; na, sodium; Plt, platelet; rBC, red blood cell; T-Bil, total bilirubin; TC, total cholesterol; TP, total 
protein; UA, uric acid; WBC, white blood cell.
Table S2 Incidence of adverse eventsa
Variables GCQID group Placebo group P-value
number of subjects eligible for safety assessment 50 50
number of subjects with adverse events 10 10 1.000
Incidence of adverse eventsa (%) 20 20 1.000
number of adverse events 14 14 1.000
Note: aIncidence of adverse events (%) =100× number of subjects with adverse events/number of subjects eligible for safety assessment.
Abbreviation: gCQID, glucosamine hydrochloride, chondroitin sulfate, quercetin glycosides, imidazole peptides, and vitamin D.
